Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
Ratios
9 Sheets · From 2023 to 2015Configuration
Margins, Growth Rates In %
| Ratio | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross Margin | - - | - - | - - | 100.00 | -624.87 | 36.66 | 88.47 | 93.52 | 94.94 | |
| Profit Margin | - - | - - | - - | -28.06 | -740.74 | 21.19 | -597.15 | -300.56 | -43.94 | |
| Operating Margin | - - | - - | - - | -35.90 | -799.10 | 18.69 | -607.78 | -314.16 | -59.51 | |
|
EPS Growth
|
- - | -141.76 | 56.34 | 93.38 | -430.77 | 131.40 | -467.69 | -8.79 | 59.23 | |
| EPS USD | -558.00 | -1,349.00 | -589.00 | -39.00 | -207.00 | 65.00 | -239.00 | -260.00 | -106.00 | |
| Return on Assets (ROA) | -45.77 | -31.97 | -18.12 | -5.47 | -35.72 | 4.43 | -20.69 | -22.32 | -12.59 | |
| Return on Equity (ROE) | 107.38 | -34.05 | -18.93 | -6.63 | -50.04 | 6.18 | -30.20 | -31.27 | -14.09 | |
| Return on Invested Capital (ROIC) | 106.68 | -34.35 | -18.68 | -10.48 | -45.53 | 5.08 | -28.76 | -30.90 | -18.16 | |
| Solvency | ||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | - - | 2.88 | 13.11 | 4.29 | 4.56 | 4.13 | 4.53 | |
| Debt/Equity | - - | - - | - - | 3.49 | 18.37 | 5.99 | 6.65 | 5.79 | 5.07 | |
| Debt/EBITDA | 185.65 | 46.36 | 242.26 | 166.31 | 4.97 | -706.29 | 79.43 | 47.73 | 41.60 | |
|
Debt/Capitalization
|
- - | - - | - - | 3.37 | 15.52 | 5.65 | 6.24 | 5.47 | 4.82 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | 14.85 | 5.28 | 5.74 | 4.84 | 4.18 | |
| Interest Debt per Share USD | - - | - - | 0.13 | 0.21 | 0.92 | 0.63 | 0.53 | 0.60 | 0.38 | |
| Debt Growth | - - | - - | - - | - - | - - | -6.81 | -8.76 | 3.07 | -13.44 | |
| Liquidity | ||||||||||
| Current Ratio | 960.38 | 1,998.19 | 2,891.89 | 1,466.59 | 948.37 | 2,086.02 | 237.21 | 377.09 | 1,364.59 | |
| Quick Ratio | 883.08 | 1,963.20 | 2,871.29 | 1,442.21 | 916.01 | 2,057.73 | 229.12 | 368.54 | 1,330.06 | |
| Cash Ratio | 883.08 | 437.66 | 1,541.76 | 235.23 | 175.21 | 707.32 | 77.59 | 59.92 | 162.99 | |
| Operating Cash Flow Ratio | -400 | -700 | -500 | 100 | -300 | 500 | - - | - - | -400 | |
| Turnover | ||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | -140.64 | - - | |
| Receivables Turnover | - - | - - | - - | 1,511.35 | - - | 5,915.74 | 3,969.09 | 2,169.26 | 12,241.89 | |
| Payables Turnover | - - | - - | - - | - - | 7,466.49 | 19,852.01 | 117.37 | 252.04 | 176.38 | |
|
Asset Turnover
|
- - | - - | - - | 19.51 | 4.82 | 20.92 | 3.47 | 7.43 | 28.64 | |
| Fixed Turnover | - - | - - | - - | 513.31 | 33.08 | 456.90 | 69.91 | 145.54 | 461.40 | |
| Coverage | ||||||||||
| Interest Coverage | - - | - - | -4,610.74 | - - | -1,400.78 | - - | - - | -2,306.38 | - - | |
| Asset Coverage | - - | - - | - - | - - | 700 | 2,300 | 1,700 | 1,800 | 2,000 | |
| Cash Flow Coverage (CFGR) | - - | - - | - - | 262.55 | -208.98 | 604.30 | -330.26 | -405.49 | -685.27 | |
| EBITDA Coverage | - - | - - | -4,600 | - - | -1,400 | - - | - - | -2,200 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -26.03 | -62.88 | -37.68 | -1.89 | -11.87 | 0.78 | -5.36 | -9.34 | -4.93 | |
|
Price/Earnings (P/E)
|
-384.12 | -159.04 | -265.40 | -5,280.27 | -842.80 | 12,831.30 | -1,865.23 | -1,070.89 | -2,029.95 | |
| Price/Earnings Growth (PEG) | - - | -1.12 | 4.71 | 56.55 | -1.96 | -97.65 | 3.99 | -121.88 | 34.27 | |
|
Price/Book (P/B)
|
-412.48 | 54.15 | 50.25 | 349.93 | 421.76 | 793.34 | 563.24 | 334.89 | 285.95 | |
| Price/Tangible Book (P/TB) | -412.48 | 54.15 | 50.25 | 349.93 | 421.76 | 793.34 | 563.24 | 334.89 | 285.95 | |
| Price/Sales (P/S) | - - | - - | - - | 1,481.55 | 6,242.95 | 2,719.33 | 11,138.30 | 3,218.62 | 891.89 | |
|
Price/Cash Flow (P/CF)
|
-428.43 | -190.45 | -305.39 | 3,818.28 | -1,098.79 | 2,193.35 | -2,564.00 | -1,426.56 | -823.48 | |
| Price/Free CF (P/FCF) | -356.01 | -175.57 | -294.35 | 4,095.56 | -982.62 | 2,209.79 | -2,464.88 | -1,329.66 | -794.75 | |
| Price/Operating CF (P/OCF) | -428.43 | -190.45 | -305.39 | 3,818.28 | -1,098.79 | 2,193.35 | -2,564.00 | -1,426.56 | -823.48 |